- Home
- RIGL vs ASIX Comparison
RIGL vs ASIX Comparison
Compare RIGL & ASIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | ASIX |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 600.1M |
| IPO Year | 2000 | 2016 |
Fundamental Metrics
Financial Performance| Metric | RIGL | ASIX |
|---|---|---|
| Price | $39.16 | $20.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $45.67 | $26.00 |
| AVG Volume (30 Days) | ★ 302.4K | 199.4K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 2.62% |
| EPS Growth | ★ 1867.68 | 11.11 |
| EPS | ★ 1.32 | N/A |
| Revenue | $294,282,000.00 | ★ $1,684,625,000.00 |
| Revenue This Year | N/A | $4.19 |
| Revenue Next Year | $12.75 | $4.60 |
| P/E Ratio | $30.67 | ★ N/A |
| Revenue Growth | ★ 64.15 | 45.49 |
| 52 Week Low | $24.84 | $14.10 |
| 52 Week High | $52.24 | $26.73 |
Technical Indicators
Market Signals| Indicator | RIGL | ASIX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About ASIX AdvanSix Inc.
AdvanSix Inc is a diversified chemistry company playing a critical role in international supply chains, innovating and delivering essential products for customers across a wide variety of end markets and applications that touch people's lives, including building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, and electronics. The company's key products include Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates. The majority of sales are from Plant Nutrients products. The company operates in the United States and internationally, with the majority of revenue coming from the United States.